top of page

UOHS 2021 Elevator Pitch Winners

$200 PRIZE

Mathieu Rheault-Henry
UOHS 2021 - 1st Place Elevator Pitch Winner 


Heart failure continues to be one of the leading causes of morbidity and mortality worldwide. The primary causative agent of chronic heart failure is myocardialinfarction which results in cardiomyocyte necrosis and the subsequent formation of fibrotic scar tissue. Currently, pharmacological and non-pharmacological therapies focus on managing symptoms of heart failure yet remain unable to reverse the underlying pathology. Heart transplantation usually cannot be relied on, as there is a major discrepancy between the availability of donors and recipients. As a result, heart failure carries a poor prognosis and high mortality rate. As the heart lacks significant endogenous regeneration potential, novel therapeutic approaches have incorporated the use of stem cells as a vehicle to treat heart failure as they possess the ability to self-renew and differentiate into multiple cell lineages and tissues. Past, present, and future clinical trials, factors that influence stem cell therapy outcomes as well as ethical and safety considerations will be discussed. Preclinical and clinical studies have shown a wide spectrum of outcomes when applying stem cells to improve cardiac function. Thismay reflect the infancy of clinical trials and the limited knowledge on the optimal cell type, dosing, route of administration, patient parameters and other important variables that contribute to successful stem cell therapy. Nonetheless, the field of stem cell therapeutics continues to advance at an unprecedented pace. We remain cautiously optimistic that stem cells will play a role in heart failure management in years to come.

$150 PRIZE

Stephanie Bogdan
UOHS 2021 - 2nd Place Elevator Pitch Winner 


Preserving biological specimens such as individual cells or biological tissues has proven to be crucial in regard to cell-based therapeutics. Unfortunately, current cryopreservation protocols remain suboptimal, reducing the potency of cellular products being developed for cell and gene therapy applications in modern medicine. To minimize cellular damage from ice recrystallization during freezing and thawing, cryopreservation techniques require the use of ice recrystallization inhibitors or cryoprotectants to help maintain cellular viability and metabolic functions post-thaw. Currently, a commonly used but relatively toxic cryoprotectant is dimethyl sulfoxide. Betaine is an organic molecule that has recently been claimed to function as a cryoprotectant. Here, we hypothesize that betaine has the ability to inhibit ice recrystallization and thus reduce cryoinjury as well as enhance post-thaw cell viability and functionality. The cryopreservation properties of commercially available betaine hydrochloride salt will be quantitatively assessed using an ice recrystallization inhibition assay and the compound’s cytotoxicity potential will be assessed using a Resazurin assay on HepG2 cell cultures. Given acceptable result profiles form these two techniques, a modified AnnexinV/Sytox ISHAGE cytometry gating strategy in appropriate adherent and non-adherent cells will be performed to measure post-thaw cell viability. If results demonstrate betaine to effectively inhibit ice recrystallization while increasing post-thaw recoveries and functionality, then this would indicate its potential for use as an ice recrystallization inhibitor instead of the relatively toxic cryoprotectant, dimethyl sulfoxide. Thus, insight obtained from this project could play a key role in implementing the use of cellular therapies in a clinical environment.

$100 PRIZE

Raisa Ladha
UOHS 2021 - 3rd Place Elevator Pitch Winner 


Race and ethnicity are determinants of health which play significant roles in shaping the quality of care and health outcomes for a child. BIPOC families disproportionately experience barriers in accessing and receiving paediatric care across Canada. The effects of these barriers are further pronounced when it is the child’s mother who serves as their proxy, ultimately setting BIPOC children on a trajectory for negative health outcomes in the future. The purpose of this study is to further understandings of how BIPOC mothers and children experience paediatric care in Ontario. It will additionally conceptualize the provider-patient relationship from the perspective of BIPOC mothers, as well as clarify their needs and expectations in order to positively engage with and receive paediatric health care services. The participant sample consists of BIPOC mothers residing in Ontario for at least 6 months, who have required paediatric care for their children (birth to age 5). 20 semi-structured interviews are being conducted and the stories that participants share will be examined through narrative analysis. Contributions of this research are 3-pronged: (1) identifying the healthcare needs of paediatric patients and their families; (2) enhancing cross-cultural understanding; (3) informing clinical practice. This study will also provide direction as to what sorts of approaches must be taken in order to sustainably implement culturally safe and collaborative paediatric care across Ontario.

bottom of page